CRL Aug 2023 195.000 put
| Previous Close | 17.70 |
| Open | 17.30 |
| Bid | 12.70 |
| Ask | 13.70 |
| Strike | 195.00 |
| Expire Date | 2023-08-18 |
| Day's Range | 17.30 - 17.70 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
ZacksHere's Why You Should Retain Charles River (CRL) Stock Now
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
Simply Wall St.Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)?
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
- Thomson Reuters StreetEvents
Q1 2023 Charles River Laboratories International Inc Earnings Call
Q1 2023 Charles River Laboratories International Inc Earnings Call
ZacksCharles River (CRL) Q1 Earnings Top Estimates, View Narrowed
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
ReutersCharles River beats profit estimates on strength in drug discovery services
Charles River Laboratories International Inc beat Wall Street estimates for first-quarter profit on Thursday, due to strong demand for its services that help clients discover new drug candidates and assess their safety. The contract research company reported revenue of $662.4 million in its discovery and safety assessment (DSA) segment, higher than analysts' average estimate of $610.9 million, according to Refinitiv data. Wilmington, Massachusetts-based Charles River said it believes its biotech clients have the funds required to take the development of their drug candidates forward, pointing to the robust demand for its DSA unit services.
ZacksCharles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksCharles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireCharles River Laboratories Announces First-Quarter 2023 Results
WILMINGTON, Mass., May 11, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.
ZacksCharles River (CRL) to Report Q1 Earnings: What's in Store?
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Business WireCharles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
WILMINGTON, Mass., May 01, 2023--Charles River launches Accugenix NGS for bacterial identification and fungal ID; announces partner lab initiative to expand global coverage.
Business WireCharles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
WILMINGTON, Mass., April 11, 2023--Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
Business WireCharles River Laboratories Showcases End-to-End Oncology Capabilities at AACR 2023
WILMINGTON, Mass., April 10, 2023--Charles River highlights the importance of next-generation technologies for oncology drug discovery at AACR 2023.
- Simply Wall St.
Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Key Insights Charles River Laboratories International's estimated fair value is US$212 based on 2 Stage Free Cash Flow...
- Reuters
Charles Rivers recommends against PETA's proposal for transparency on lab monkeys
The board of Charles River Laboratories has unanimously recommended against a shareholder proposal requiring transparency on its import practices of lab monkeys, according to a regulatory filing by the U.S. contract research organization firm. The proposal, brought forward by animal rights non-profit PETA, suggests Charles River annually disclose the species and the country of origin of the non-human primates (NHP) that it imports into the United States as a part of animal research services it offers to drug developers. PETA's proposal also demands information on whether the monkeys are caught in the wild or bred in captivity.
ZacksWhy Is Charles River (CRL) Down 14.8% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
The total return for Charles River Laboratories International (NYSE:CRL) investors has risen faster than earnings growth over the last five years
It might be of some concern to shareholders to see the Charles River Laboratories International, Inc. ( NYSE:CRL...
- Zacks
Charles River's (CRL) New Cloud Platform Offers Real-Time Data
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
ZacksCharles River (CRL) Advances CDMO Portfolio With Latest Offer
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
Business WireCharles River Laboratories to Present at Barclays Global Healthcare Conference
WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference
Business WireCharles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
WILMINGTON, Mass., March 13, 2023--Charles River launches Apollo, an intuitive customer platform that provides secure cloud-based access to real-time toxicology study data.
Business WireCharles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
WILMINGTON, Mass., March 09, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.
- Simply Wall St.
Richard Wallman Is The Independent Director of Charles River Laboratories International, Inc. (NYSE:CRL) And They Just Picked Up 9.1% More Shares
Investors who take an interest in Charles River Laboratories International, Inc. ( NYSE:CRL ) should definitely note...
- Simply Wall St.
Charles River Laboratories International Full Year 2022 Earnings: Beats Expectations
Charles River Laboratories International ( NYSE:CRL ) Full Year 2022 Results Key Financial Results Revenue: US$3.98b...
- Reuters
UPDATE 1-Charles River gets DoJ subpoena on Cambodian supply of lab monkeys
Charles River Laboratories said on Wednesday that it had received a subpoena from the U.S. Department of Justice over an investigation into the supply of non-human primates from Cambodia, which are a part of the animal research services that the company offers to drug developers. The DoJ had in November charged members of an international primate smuggling ring with multiple felonies for their role in bringing wild long-tailed macaques into the United States. Charles River expects constraints on the supply of monkeys to reduce its consolidated revenue growth forecast by about 200 to 400 basis points this year.
ZacksCharles River (CRL) Q4 Earnings Top Estimates, Margins Dip
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.